156 related articles for article (PubMed ID: 11912023)
1. Anti-fungal therapy at the HAART of viral therapy.
Munro CA; Hube B
Trends Microbiol; 2002 Apr; 10(4):173-7. PubMed ID: 11912023
[TBL] [Abstract][Full Text] [Related]
2. HIV proteinase inhibitors: do they really work against Candida in a clinical setting?
Cassone A; Cauda R
Trends Microbiol; 2002 Apr; 10(4):177-8. PubMed ID: 11912024
[No Abstract] [Full Text] [Related]
3. Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility.
De Bernardis F; Tacconelli E; Mondello F; Cataldo A; Arancia S; Cauda R; Cassone A
FEMS Immunol Med Microbiol; 2004 May; 41(1):27-34. PubMed ID: 15094164
[TBL] [Abstract][Full Text] [Related]
4. Oral thrush and HIV protease inhibitors.
Stricker RB; Goldberg B
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):105-6. PubMed ID: 10534155
[No Abstract] [Full Text] [Related]
5. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients.
Korting HC; Schaller M; Eder G; Hamm G; Böhmer U; Hube B
Antimicrob Agents Chemother; 1999 Aug; 43(8):2038-42. PubMed ID: 10428932
[TBL] [Abstract][Full Text] [Related]
6. The secreted aspartic proteinases as a new target in the therapy of candidiasis.
Bein M; Schaller M; Korting HC
Curr Drug Targets; 2002 Oct; 3(5):351-7. PubMed ID: 12182226
[TBL] [Abstract][Full Text] [Related]
7. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.
Bektić J; Lell CP; Fuchs A; Stoiber H; Speth C; Lass-Flörl C; Borg-von Zepelin M; Dierich MP; Würzner R
FEMS Immunol Med Microbiol; 2001 Jul; 31(1):65-71. PubMed ID: 11476984
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects.
Cassone A; Tacconelli E; De Bernardis F; Tumbarello M; Torosantucci A; Chiani P; Cauda R
J Infect Dis; 2002 Jan; 185(2):188-95. PubMed ID: 11807692
[TBL] [Abstract][Full Text] [Related]
9. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.
Migliorati CA; Birman EG; Cury AE
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):301-10. PubMed ID: 15356467
[TBL] [Abstract][Full Text] [Related]
10. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study.
Hoegl L; Thoma-Greber E; Röcken M; Korting HC
Mycoses; 1998; 41(7-8):321-5. PubMed ID: 9861838
[TBL] [Abstract][Full Text] [Related]
11. Oral candidiasis of HIV-infected children undergoing sequential HIV therapies.
Melo NR; Taguchi H; Culhari VP; Kamei K; Mikami Y; Smith SN; Vilela MS
Med Mycol; 2009 Mar; 47(2):149-56. PubMed ID: 18651304
[TBL] [Abstract][Full Text] [Related]
12. The impact of HIV-protease inhibitors on opportunistic parasites.
Pozio E; Morales MA
Trends Parasitol; 2005 Feb; 21(2):58-63. PubMed ID: 15664527
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
Cassone A; De Bernardis F; Torosantucci A; Tacconelli E; Tumbarello M; Cauda R
J Infect Dis; 1999 Aug; 180(2):448-53. PubMed ID: 10395861
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of virulence factors of Candida albicans isolated from HIV-positive individuals using HAART.
de Paula Menezes R; de Melo Riceto ÉB; Borges AS; de Brito Röder DV; dos Santos Pedroso R
Arch Oral Biol; 2016 Jun; 66():61-5. PubMed ID: 26913969
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes.
Tavanti A; Pardini G; Campa D; Davini P; Lupetti A; Senesi S
J Clin Microbiol; 2004 Oct; 42(10):4726-34. PubMed ID: 15472333
[TBL] [Abstract][Full Text] [Related]
16. Enzyme production by Candida albicans and Candida dubliniensis in periodontal HIV-positive patients receiving and not receiving antiretroviral therapy.
Dubois VA; González MI; Martínez ME; Fedelli L; Lamas S; D Eramo LR; Squassi AF; Sánchez GA; Salgado P; Gliosca LA; Molgatini SL
Acta Odontol Latinoam; 2020 Sep; 33(2):104-111. PubMed ID: 32920612
[TBL] [Abstract][Full Text] [Related]
17. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
18. Oral mycoses and other opportunistic infections in HIV: therapy and emerging problems - a workshop report.
Vidya KM; Rao UK; Nittayananta W; Liu H; Owotade FJ
Oral Dis; 2016 Apr; 22 Suppl 1():158-65. PubMed ID: 27109283
[TBL] [Abstract][Full Text] [Related]
19. Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis.
Schaller M; Korting HC; Schäfer W; Bastert J; Chen W; Hube B
Mol Microbiol; 1999 Oct; 34(1):169-80. PubMed ID: 10540295
[TBL] [Abstract][Full Text] [Related]
20. Dynamic analysis of oral Candida carriage, distribution, and antifungal susceptibility in HIV-infected patients during the first year of highly active antiretroviral therapy in Guangxi, China.
Jiang L; Yong X; Li R; Peng Y; Liu W; Qin Q; Zhang L; Liu Z; Liang H; Tao R
J Oral Pathol Med; 2014 Oct; 43(9):696-703. PubMed ID: 24931443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
